Natriumlevofolinat Medac (Levoleucovorin Disodium)

Levoleucovorin Disodium is a reduced form of folic acid that bypasses the dihydrofolate reductase block caused by methotrexate. By directly replenishing tetrahydrofolate pools, it restores DNA synthesis in healthy cells and stabilises the ternary complex of 5‑fluorouracil with thymidylate synthase, thereby increasing the drug’s cytotoxic effect on tumour cells.

The dose of Natriumlevofolinat Medac is determined by the prescribing clinician based on the specific indication, patient weight, renal function and the timing of concurrent chemotherapy. Healthcare professionals should follow institutional protocols and product labeling when calculating the appropriate regimen.

Safety data for levoleucovorin in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

The primary alternative is calcium leucovorin (folinic acid). Both provide reduced folate, but levoleucovorin is the levo‑isomer, offering higher affinity for cellular transporters and potentially more efficient intracellular conversion. Clinical choice depends on formulation preferences, stability, and specific institutional protocols.

The product must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the solution reaches room temperature for a short period during preparation, it should be used promptly and not re‑refrigerated.

Natriumlevofolinat Medac is given by intravenous infusion. The exact infusion rate and duration are defined by the treating physician, often based on the timing relative to methotrexate or fluoropyrimidine administration. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy.

Serious adverse events, although rare, include anaphylactic or severe hypersensitivity reactions, acute renal impairment, significant hepatic dysfunction, severe electrolyte disturbances, and thromboembolic events. Prompt recognition and discontinuation of the drug are essential if any of these reactions occur.

Patients with known hypersensitivity to levoleucovorin, its excipients, or other folate analogues should avoid the product. Those with severe renal impairment where adequate clearance cannot be ensured, or with uncontrolled hepatic disease, may also be contraindicated. Clinical judgment is required for each individual case.